Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 15/20 | 0.74 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | PGR | P06401 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1772402 | 0.99 | AR (0.72) | ARPOLBPGR | |
| SCHEMBL1773606 | 0.99 | AR (0.72) | ARPOLBPGR | |
| SCHEMBL1773994 | 0.98 | AR (0.74) | ARPGR | |
| SCHEMBL632960 | 0.95 | AR (0.73) | ARPGR | |
| SCHEMBL20003377 | 0.91 | AR (0.61) | ARPGR | |
| SCHEMBL1716347 | 0.91 | AR (0.61) | AR | |
| SCHEMBL8925935 | 0.91 | AR (0.65) | ARPGR | |
| SCHEMBL1772431 | 0.91 | AR (0.67) | ARPGR | |
| SCHEMBL8173932 | 0.90 | AR (0.60) | ARPGR | |
| SCHEMBL8926439 | 0.90 | AR (0.66) | ARPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5750553-A | ANTIANDROGENIC AGENTS | ROUSSEL UCLAF (FR) | 1998-05-12 | — | — | US | claimed |
| JP-H09507241-A | — | — | 1997-07-22 | — | — | JP | claimed |
| EP-0738263-A1 | NOVEL OPTIONALLY SUBSTITUTED PHENYLIMIDAZOLIDINES, INTERMEDIATES AND PROCESS FOR THEIR PREPARATION, THEIR USE AS DRUGS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ROUSSEL UCLAF (FR) | 1996-10-23 | — | — | EP | claimed |
| WO-1995018794-A1 | NOVEL OPTIONALLY SUBSTITUTED PHENYLIMIDAZOLIDINES, INTERMEDIATES AND PROCESS FOR THEIR PREPARATION, THEIR USE AS DRUGS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ROUSSEL UCLAF (FR) | 1995-07-13 | — | — | WO | claimed |
| US-20110112097-A1 | Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | SANOFI-AVENTIS (FR) | 2011-05-12 | — | — | US | disclosed |
| US-5750553-A | ANTIANDROGENIC AGENTS | ROUSSEL UCLAF (FR) | 1998-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112097-A1 | Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | GIPR, PGC, DDC | AR 2449/4885POLB 3357/4885PGR 1536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.